
What megalodon really ate to meet its 100,000-calorie daily requirement, according to a new study
CNN —
What scientists understand about the voracious feeding habits of the colossal megalodon could be up for some revision.
The prehistoric predator that went extinct about 3.6 million years ago was not hunting only large marine mammals such as whales as researchers widely thought, a new study has found. Instead, minerals in fossilized teeth reveal that megalodon might have been an opportunistic feeder to meet its remarkable 100,000-calorie-per-day requirement.
'When available, it would probably have fed on large prey items, but when not available, it was flexible enough to feed also on smaller animals to fulfill its dietary requirements,' said lead study author Jeremy McCormack, a geoscientist at Goethe University in Frankfurt, Germany.
The study, published Monday in the journal Earth and Planetary Science Letters, also showed there were regional differences in the giant shark's feeding habits. The finding suggests megalodon would pursue whatever was in local waters, devouring other top predators and smaller prey alike.
'They were not concentrating on certain prey types, but they must have fed throughout the food web, on many different species,' McCormack said. 'While certainly this was a fierce apex predator, and no one else would probably prey on an adult megalodon, it's clear that they themselves could potentially feed on almost everything else that swam around.'
Megalodon dispatched its prey with a ferocious bite and lethal, serrated teeth that could reach up to 7 inches (18 centimeters) long — the size of a human hand. The superpredator's teeth — abundant in the fossil record — are what McCormack and his colleagues used to conduct a geochemical analysis, unlocking fresh clues that could challenge megalodon's role as sole king of the ancient seas.
Zinc in megalodon teeth
It's not the first time that a study has challenged previous knowledge about the enormous sea creature. In fact, many questions remain unanswered about Otodus megalodon — its scientific species name meaning 'giant tooth' — since no complete fossil has ever been discovered. The lack of hard evidence stems from the fact that fish skeletons are made of softer cartilage rather than bone, so they don't fossilize very well.
Recent research found that the animal was more warm-blooded than other sharks, for example, and there is an ongoing debate about its size and shape. Scientists who created a 3D reconstruction suggest ed in 2022 that megalodon was about three times as long as a great white shark — about 52 feet (16 meters). However, a March study hypothesized that the megashark was actually much larger — up to 80 feet (24 meters) in length and even longer than the fictional version in the 2018 blockbuster 'The Meg,' which suggested the ancient predator was 75 feet (23 meters) from head to tail.
As for megalodon's feeding habits, determining what it ate based on fossil evidence poses challenges, according to McCormack. 'We know that they fed on large marine mammals from tooth bite marks,' he said. 'Of course, you can see bite marks on the bones of marine mammals, but you will not see them if they fed on other sharks, because sharks don't have bones. So there's already a bias in this kind of fossil record.'
To glean more about megalodon's prey selection, McCormack and his coauthors looked at the giant shark's fossilized teeth and compared them with those of other animals that lived at the same time, as well as teeth from modern sharks and other predators such as dolphins. The researchers used specimens from museum collections and samples from beached animal carcasses.
Specifically, the study team conducted a lab analysis of zinc, a mineral that is acquired only through food.
Zinc is essential for living organisms and plays a crucial role in tooth development. The ratio of heavy and light zinc isotopes in the sharks' tooth enamel preserves a record of the kind of animal matter that they ate.
Different types, or isotopes, of zinc are absorbed when fish and other animals eat, but one of them — zinc-66 — is stored in tooth enamel much less than another, zinc-64. The ratio between those zinc isotopes widens the further away an animal gets from the lowest level of the food chain. That means that a fish eating other fish would have lower levels of zinc-66 compared with zinc-64, and the fish that eat those fish will have even less zinc-66 compared with zinc-64, creating ratio markers that can help draw up a sequence of the food chain.
The researchers found that sea bream, a fish that feeds on mussels and crustaceans, was at the bottom of their reconstructed chain, followed by smaller sharks from the Carcharhinus genus, up to 9.8 feet (3 meters) in length, and extinct toothed whales comparable in size to modern dolphins.
Farther up were larger sharks such as the Galeocerdo aduncus, similar to a modern tiger shark, and occupying the top slot was megalodon — but its zinc ratios were not so different as to suggest a massive gap with the lower-tier animals, meaning they might have been part of megalodon's diet, too. 'Based on our new results, we see that it was clear it could feed at the very top, but it was flexible enough to feed also on lower (levels of the food chain),' McCormack said.
In addition, the researchers found megalodon was not alone at the top of the food chain but instead shared the spot with other 'opportunistic supercarnivores' such as its close relative Otodus chubutensis and the lesser-known Araloselachus cuspidatus, another giant fish-eating shark.
That revelation challenges the assumption that megalodon was the exclusive ruler of the oceans and draws comparisons with the great white shark, another large opportunistic feeder. The finding also reinforces the idea that the rise of the great white may have been a factor in megalodon's extinction, according to paleobiologist Kenshu Shimada, one of the coauthors of the latest study.
'One of the contributing factors for the demise of megalodon has been hypothesized to be the rise of the great white shark, which feeds on fish when young and shifts its diet to marine mammals as it becomes larger,' said Shimada, a professor of biological and environmental sciences at DePaul University in Chicago.
'Our new study, that demonstrates the 'diet overlap' between the great white shark and megalodon, strengthens the idea that the evolution of the smaller, likely more agile and maneuverable great white shark could have indeed (driven) megalodon to extinction.'
Megalodon vs. great white shark
The new research allows scientists to recreate a snapshot of the marine food web that existed about 20 million years ago, according to Jack Cooper, a UK-based paleobiologist and megalodon expert who wasn't involved with the study.
'The general picture of megalodon has been of a gigantic shark munching on whales,' Cooper said in an email. 'This study adds a new dimension that megalodon probably had a wide range of prey — essentially, it probably ate not just whales but whatever it wanted.'
Another interesting find, he added, is that megalodon's diet probably varied slightly between different populations, something observed in today's great white sharks. 'This makes sense and is something we would have probably expected since megalodon lived all over the world and not all of its prey items would have done; but it's wonderful to have concrete data supporting this hypothesis,' Cooper said.
The study adds to a growing body of evidence that is reshaping commonly held beliefs about megalodon and its close relatives, said Alberto Collareta, a researcher in the department of Earth sciences at Italy's University of Pisa who was not involved in the research.
'These have led us to abandon traditional reconstruction of the megatooth sharks as 'inflated' versions of the modern white shark. We now know that the Megalodon was something else — in terms of size, shape and ancestry, and of biology, too,' Collareta said via email.
'The Miocene (palaeo)ecosystems in question did not work in a radically different way compared to their modern counterparts — even if they feature … completely extinct protagonists such as the megatooth sharks,' he added, highlighting what he found to be the report's key takeaway.
'That said, it is still useful to acknowledge that our understanding of the Meg is essentially limited to its ubiquitous teeth, a few vertebrae and a handful of scales. What I'd really love to see emerging from 'the foggy ruins of time' is a complete Meg skeleton… Let's hope that the fossil record will amaze us once again.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Scientists Discover 'Deceptively Cute' Prehistoric Species That Looked Like a Pokémon
Scientists have identified a new species of ancient whale with cartoonish bulging eyes that they say would have made it look like a Pokémon. A precursor to today's modern whale species, the 25 million-year-old creature was "deceptively cute," according to Erich Fitzgerald, senior curator of vertebrate paleontology at Australia's Museums Victoria Research Institute, as reported by the Toronto Sun. "It might have looked for all the world like some weird kind of mash-up between a whale, a seal and a Pokémon," Fitzgerald said, before clarifying, "but they were very much their own thing." While the species, officially named Janjucetus dullardi, might have looked like something you could pop out of a Pokéball, in reality they would have been something you'd probably want to stay clear of. Described as a feral predator with a super effective bite, the specimen is estimated to have once been around the size of a single bed, despite only being a juvenile. Still, much of the species' full appearance remains a mystery, as only a partial skull and teeth have so far been found. "They may have had tiny little nubbins of legs just projecting as stumps from the wall of the body," Fitzgerald continued. Adorable! Janjucetus dullardi has been placed as a member of the rare mammalodontids group of ancient whales that existed 34-23 million years ago, which later evolved into the humpbacks and minke whales of today. Or in Pokémon terms, it would have definitely been Water-type. The species has been named after amateur fossil hunter and high school principal Ross Dullard, who contacted Museums Victoria after unearthing the skull on a local beach. Confirming it did indeed belong to a previously-unknown species has since taken six years of research — a lot longer than simply registering it to a Pokédex. This week, however, has finally brought that confirmation — something Dullard says has given him "the greatest 24 hours of my life" and "high fives coming left, right and center" when he was greeted on his high school campus the following day. "That's taken my concentration for six years," Dullard said. "I've had sleepless nights. I've dreamt about this whale." Now, how about returning it to life, Helix Fossil style? Tom Phillips is IGN's News Editor. You can reach Tom at tom_phillips@ or find him on Bluesky @ Solve the daily Crossword
Yahoo
4 hours ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 hours ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future